Close Window
Laurus Labs Aptuit Laurus Labs Click here if you do not want to see this message again
Bookmark Page
Get Adobe Flash player

This page requires Flash Player version 8.0.24 or higher.

Get In Touch
Contact Aptuit
Email
Email us at info@aptuit.com
Email
For general sales & enquiries
USA +1 855 506 6360
EUROPE +39 045 8219333
Email
Alternatively, contact one of our
facilities directly
Greenwich HQ +1 203 422 6600 Oxford +44 1235 433600
Glasgow +44 141 945 8400 Verona +39 045 8218111
Harrisonville +1 816 380 3121 Visakhapatnam +91 3061222
Hyderabad +91 40 39804333 West Lafayette +1 765 463 0112
Contact Aptuit Footer
Printer Friendly Text Only Page
A
A
A

Press Releases

Blue underline
Close
Forward to a Friend
Simply fill in the fields below and we will email your friend/colleague a link to this page:
Your friend/colleague's name:  
Your friend/colleague's email address:    
Your Name:  
Close
Solid State Chemistry Educational Survey
Solid State Chemistry plays a very important role in the development of a drug. This includes polymorphs, cocrystals, salts and amorphous materials as well as the analysis of an API and a drug formulation with regard to their solid-state chemistry properties.

Please help us to gauge the industry's interest in an educational Solid State Chemistry course by participating in the survey:
Solid State Chemistry Educational Survey - 10% Discount
Please click here to fill in the questionnaire and register for your 10% discount off any Aptuit hosted short courses.
Solid State Chemistry Educational Survey - Anonymous
Please click here to fill in the questionnaire
anonymously.
No thanks
To register for your 10% discount off any Aptuit hosted short course please fill in your details below:
Your first name:  
Your last name:  
Your company
name:  
Your email
address:    
Your contact
phone number:  
Your country:  
Simply check the most appropriate answer box for each question and click submit when you have finished:
Have you ever attended an SSCI short course?  
If yes, please rate your experience:
(from 1:Poor to 5:Outstanding)
If no, why not?
Would you be interested in a short course on Solid State Chemistry?  
What would be the ideal length of a course of this nature?
Would you be willing to pay for the educational course, if so up to how much?  
Would you be willing to travel to the course?
What level of knowledge should the course cover?
What do you normally look for when attending these types of events?
(check all that apply)




Solid State Chemistry plays a very important role in the development of a drug. This includes polymorphs, cocrystals, salts and amorphous materials as well as the analysis of an API and a drug formulation with regard to their solid-state chemistry properties.

Please provide any specific topics you would like to see covered in a course of this nature:  
Please provide the names of any specific speakers you would like to see present at the course, e.g. leading academics, representatives from government:  
Simply check the most appropriate answer box for each question and click submit when you have finished:
Have you ever attended an SSCI short course?  
If yes, please rate your experience:
(from 1:Poor to 5:Outstanding)
If no, why not?
Would you be interested in a short course on Solid State Chemistry?  
What would be the ideal length of a course of this nature?
Would you be willing to pay for the educational course, if so up to how much?  
Would you be willing to travel to the course?
What level of knowledge should the course cover?
What do you normally look for when attending these types of events?
(check all that apply)




Solid State Chemistry plays a very important role in the development of a drug. This includes polymorphs, cocrystals, salts and amorphous materials as well as the analysis of an API and a drug formulation with regard to their solid-state chemistry properties.

Please provide any specific topics you would like to see covered in a course of this nature:  
Please provide the names of any specific speakers you would like to see present at the course, e.g. leading academics, representatives from government:  
Solid State Chemistry Educational Survey


Thank you


Your comments are appreciated. If you have registered for your 10% discount, please claim this at the time of booking your Aptuit-hosted course.
Close

GSK and Aptuit finalize agreement for Aptuit to acquire GSK’s research operations in Italy

07.01.2010

GSK and Aptuit finalize agreement for Aptuit to acquire GSK’s research operations in Italy

  • Augments Aptuit’s global, integrated scientific and operational capabilities and preserves scientific expertise at the centre

London, UK and Greenwich Connecticut, US, July 1, 2010 – GlaxoSmithKline (GSK) and Aptuit, Inc. announced today that they have finalized an agreement for Aptuit to acquire operations at GSK’s Medicines Research Centre in Verona, Italy

The arrangement, which is effective as of July 1, 2010, provides for ongoing employment of the staff at the centre and for Aptuit to supply GSK with R&D services from the facilities . Financial terms have not been disclosed.

Under the agreement, Aptuit will gain the scientific expertise and knowledge at the research centre through the transfer of the facility’s approximately 500 staff from GSK to Aptuit. This will help maintain the life sciences research and talent pool in Italy. In addition to becoming an important member of GSK’s contract research organization network, acquisition of the operations will also allow Aptuit to provide integrated development services to its global customers. 

“Aptuit was built to provide an integrated drug development capability and streamline the drug development process. This is a strategic acquisition of GSK’s research business in Verona that further strengthens scientific expertise and capabilities within Aptuit, extending our integrated discovery and development offerings,” said Tim Tyson, Chairman and CEO of Aptuit. “This partnership is an example of the developing new model of outsourced R&D collaborations. Verona staff are recognized industry-wide for their drug development expertise and will be an excellent addition to the Aptuit team. ”

GSK announced in February its proposal to cease discovery research in select neurosciences areas such as pain and depression, which impacted research at the Italian facility.

Moncef Slaoui, Chairman of GSK Research and Development said: “I am pleased that both GSK and Aptuit have developed this innovative approach. It provides a modern option for drug discovery expertise to remain as part of the science research community in Italy and offers the opportunity to assure continuity of employment for the GSK staff at the site. This arrangement would not have been possible without the input of the Italian government and unions.”

The Verona Medicines Research Centre expands Aptuit’s global footprint to 19 locations – a global network of operations that provides a full suite of development services. The agreement also enhances Aptuit’s ability to serve customers working to develop compounds for high-value and strategically important therapeutic areas such as neurosciences discovery and development, as well as cardiovascular and infectious diseases.  

Aptuit will combine its existing capabilities with the Verona Medicines Research Centre’s expertise in drug discovery, lead optimization, active pharmaceutical ingredient (API) development and manufacturing, and pre-clinical and clinical drug development. This will create a unique, industry-leading drug development capability.  

About Aptuit:

Aptuit, Inc. is a global pharmaceutical services company focused on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit’s employees deliver an integrated suite of product development services to more than 800 companies worldwide, driven by a deep commitment to client service, quality, and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information about Aptuit, please visit www.aptuit.com , for more information about Aptuit’s acquisition of the Verona Medicines Research Centre operations, please visit http://www.aptuit.com/Verona

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

For Media enquires contact

Joanna Disley, Aptuit Director, Marketing Services         joanna.disley@aptuit.com
Krystle Fico, Feinstein Keen Healthcare                         krystle.ficco@fkhealth.com

Home| Contact| About Us| Resource Library| Legal| Privacy| Site Map
© 2012 Aptuit LLC All Rights Reserved.